Strategic partnerships Sintetica has recently engaged in exclusive and milestone partnerships with distributors and pharmaceutical players, including FFF Enterprises for Lidocaine Hydrochloride Injection and collaboration with EIT Health. Leverage these alliances to identify co-marketing, distribution, or contracted supply opportunities in anesthesia and local anesthetics across US and Europe.

US market entry The launch of Lidocaine Hydrochloride Injection via Sintetica US marks a concrete US market entry. Target hospital networks, ambulatory surgery centers, and regional distributors with injectable anesthetic needs and broader local anesthetic portfolios.

Innovation focus Sintetica concentrates on innovations in anaesthesia, pain management, intensive care, and neuromodulation. Explore opportunities to align with R&D collaborators or contract manufacturing for novel delivery systems, specialty injectables, or combined therapeutics.

Financial scale With revenue in the range of tens of millions and a mid-sized employee base, Sintetica presents a high-potential target for supply agreements, manufacturing partnerships, and scalable distribution deals without the complexity of megacorporations.

Industry positioning As a Swiss pharma player with established international ties and backing from strategic investors, Sintetica is positioned to pursue licensing, licensing-in/out, or joint ventures with larger partners seeking specialty injectable capabilities in anesthesia and neuromodulation.